Tina Cascone et al, 2025.
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase II NeoCOAST-2 trial
Nature Medicine
Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its executive team will present and host 1x1 meetings at the upcoming investor...
Outcome of Innate Pharma’s 2025 Annual General Meeting
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”), which took place on May 22...
Christian ITIN
CEO of Autolus
Innate Pharma highlights durable responses to lacutamab in Sezary syndrome and mycosis fungoides
Long term follow-up data from the TELLOMAK Phase 2 trial in Sézary syndrome (SS) and mycosis fungoides (MF) will be presented at the ASCO Annual Meeting 2025. Long-term follow-up data from TELLOMAK...
Marty J. DUVALL
Experienced biotech CEO and global builder of biotech brands
Innate Pharma highlights abstracts selected for ASCO 2025 annual meeting
Long term follow-up results of TELLOMAK Phase 2 trial in Sézary syndrome and mycosis fungoides Trial in Progress poster on IPH4502, Innate’s differentiated ADC in development in advanced solid tumors...
Innate Pharma highlights ANKET® abstracts selected for the EHA 2025 congress
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that an abstract regarding IPH6501, its ANKET® targeting CD20 B cells currently developed in...
Innate Pharma reports first quarter 2025 business update and financial results
€15 million investment by Sanofi, in addition to the ongoing partnership including the development of BCMA targeting ANKET ® program in autoimmune indications First patient dosed in a Phase 1 study...